Jay Sitgreaves, MBA

Based in Knoxville, TN, Jay serves as the Chief Operating Officer at New Day Diagnostics, a life sciences company focused on delivering innovative, accessible diagnostic solutions. In this role, he leads company-wide operational strategy and execution, ensuring that scientific innovation translates into scalable, patient-centered diagnostic products. New Day Diagnostics is known for launching ColoHealth™, the first FDA-approved blood-based screening test for colorectal cancer, and its custom-tailored bioresearch services for clinical diagnostic trials. New Day Diagnostics is rapidly expanding its portfolio to include diagnostics for axial spondyloarthritis, celiac disease, H. pylori, respiratory infections, and hepatocellular carcinoma. As COO, Jay is responsible for: • Operational Leadership: Overseeing CLIA-certified and ISO 13485:2016-compliant laboratory operations to maintain the highest standards of quality and efficiency. • Strategic Partnerships: Supporting the expansion of global reach through strategic alliances, including collaborations with companies like Augurex Life Sciences and Hepion Pharmaceuticals. • Product Development & Commercialization: Driving the development and deployment of next-generation diagnostics such as ColoPlexPLUS™, a multiomic screening panel for early disease detection. • Scaling Distribution: Managing the decentralized fulfillment and logistics infrastructure to deliver remote, accessible diagnostics to diverse healthcare markets—including physician offices, employer wellness programs, and direct-to-consumer channels. Operating out of the company’s new purpose-built laboratory in University of Tennessee Research Park, New Day Diagnostics is strategically positioned at the intersection of medical research and commercial development. Through his leadership, the company continues to redefine preventative care by making diagnostic insights more actionable, affordable, and available to the patients who need them most.

As Senior Vice President of Operations at LUX Enterprise, Jay Sitgreaves, MBA, leads strategic growth, operational efficiency, and market expansion across the company’s subsidiaries, including LUX Diagnostics and LUX Therapeutics. With expertise in sales, marketing, and business development, he drives initiatives that enhance supply chain logistics, streamline processes, and strengthen financial planning. Jay works closely with executive leadership to ensure regulatory compliance, optimize market strategy, and foster innovation in diagnostics and regenerative medicine. Passionate about mentorship and leadership development, he is committed to building high-performing teams and positioning LUX Enterprise for long-term success.

As Senior Vice President of Operations at LUX Diagnostics, Jay Sitgreaves, MBA, leads strategic initiatives that enhance operational efficiency, optimize market expansion, and drive sustainable growth. With expertise in sales, marketing, and business development, he spearhead efforts to improve supply chain logistics, streamline laboratory processes, and strengthen financial planning to support high-quality, accessible diagnostic solutions. Collaborating closely with executive leadership, Jay Sitgreaves, MBA, ensures regulatory compliance, operational excellence, and cutting-edge innovation in molecular and clinical diagnostics. My passion for mentorship and leadership development fuels my commitment to building high-performing teams that advance LUX Diagnostics’ mission of delivering reliable, rapid, and scalable testing solutions to meet evolving healthcare needs.

As Senior Vice President of Operations at LUX Therapeutics, Jay Sitgreaves, MBA, drives strategic growth, operational excellence, and market expansion in the rapidly evolving field of regenerative medicine and advanced cellular therapies. With expertise in sales, marketing, and business development, I lead initiatives that optimize supply chain logistics, enhance clinical partnerships, and streamline operational efficiencies to support cutting-edge patient care solutions. Working closely with executive leadership, Jay Sitgreaves, MBA, ensure regulatory compliance, financial sustainability, and innovation in personalized medicine. Passionate about mentorship and leadership development, he committed to building high-performing teams that support LUX Therapeutics’ mission of delivering life-changing regenerative therapies that improve patient outcomes.

As Senior Vice President of Operations at OmniTox DNA, Jay Sitgreaves, MBA, leads strategic growth, operational efficiency, and market expansion in the field of advanced toxicology and molecular testing. With expertise in sales, marketing, and business development, he drives initiatives that enhance supply chain logistics, laboratory operations, and financial planning to support high-quality, science-driven testing solutions. Collaborating with executive leadership, Jay Sitgreaves, MBA, ensure regulatory compliance, innovative market strategies, and seamless operational execution to advance precision toxicology and DNA-based testing. Passionate about mentorship and leadership development, he is committed to building high-performing teams that drive OmniTox DNA’s mission of delivering accurate, timely, and reliable toxicology insights that support healthcare, legal, and workplace safety decisions.

Responsible for expanding the growth of AvuTox through the Southern United States through acquisition of skilled sales professionals.

Build and increase a territory within my region through new client sales while maintaining existing client relationships.